Struthers Richard Scott's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Dec 4, 2024
- Accession no.
- 0000950170-24-133297
- Filed
- Dec 4, 2024
- Trade date
- Dec 2, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $575.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Struthers Richard ScottCIK 0001746298 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | Common Stock | SSaleDisposed | −10,000 | $57.57F2 | −$575,700 | 100,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $57.57 per share. The range of sales prices on the transaction date was $56.90 to $58.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.